[Skip to Content]
[Skip to Content Landing]

July 2019 - April 2015

Decade

Year

Issue

September 2018, Vol 4, No. 9, Pages 1153-1307

Original Investigation

Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer

Abstract Full Text
open access has active quiz
JAMA Oncol. 2018;4(9):1179-1186. doi:10.1001/jamaoncol.2018.1621

This cohort study examines whether an assay for the nuclear-localized androgen receptor splice variant 7 protein in circulating tumor cells can be used to estimate overall survival among patients with metastatic castration-resistant prostate cancer treated with taxanes vs androgen receptor signaling inhibitors.

Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial

Abstract Full Text
open access
JAMA Oncol. 2018;4(9):1189-1197. doi:10.1001/jamaoncol.2018.0775

This secondary analysis of tumor specimens collected for the LUX-Lung 8 randomized clinical trial assesses whether ERBB gene mutations of family members were associated with outcomes among patients with lung squamous cell carcinoma randomized to treatment with afatinib or erlotinib.

Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The SOLD Randomized Clinical Trial

Abstract Full Text
open access
JAMA Oncol. 2018;4(9):1199-1206. doi:10.1001/jamaoncol.2018.1380

This randomized clinical trial evaluates the efficacy and safety of adjuvant trastuzumab continued beyond chemotherapy for a duration of 9 weeks vs 1 year in women with HER2-positive early breast cancer treated with up-front chemotherapy containing a taxane and trastuzumab.

Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer

Abstract Full Text
JAMA Oncol. 2018;4(9):1207-1213. doi:10.1001/jamaoncol.2018.1436

This single-arm, open-label trial evaluates the safety and efficacy of the anti–epidermal growth factor receptor antibody panitumumab plus neoadjuvant chemotherapy (nab-paclitaxel and carboplatin followed by fluorouracil, epirubicin, and cyclophosphamide) in patients with primary HER2-negative inflammatory breast cancer.

Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial

Abstract Full Text
JAMA Oncol. 2018;4(9):1214-1220. doi:10.1001/jamaoncol.2018.1812

This clinical trial investigates the maximum tolerated dosage of tucatinib combined with ado-trastuzumab emtansine in the treatment of patients with ERBB2/HER2-positive metastatic breast cancer with and without brain metastases.

Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016

Abstract Full Text
open access
JAMA Oncol. 2018;4(9):1221-1227. doi:10.1001/jamaoncol.2018.2128

This systematic analysis reports incidence, mortality, and disability-adjusted life-year (DALY) estimates from the Global Burden of Disease 2016 study to characterize the burden of multiple myeloma and the availability of effective therapies for 21 world regions and 195 countries and territories from 1990 to 2016.

Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma

Abstract Full Text
JAMA Oncol. 2018;4(9):1228-1235. doi:10.1001/jamaoncol.2018.1986

This cohort study examines the prevalence of germline mutations in patients with known renal cell carcinoma predisposition genes and other cancer-associated genes and identifies clinical and pathologic factors associated with germline mutations.

Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors

Abstract Full Text
open access has audio
JAMA Oncol. 2018;4(9):1237-1244. doi:10.1001/jamaoncol.2018.1701

This tumor database study examines the prevalence of PDL1 amplification and its utility as a response biomarker to PD-1/PD-L1 blockade in solid tumors.

Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse

Abstract Full Text
JAMA Oncol. 2018;4(9):1245-1253. doi:10.1001/jamaoncol.2018.2091

This registry-based study compares survival in patients with acute myelogenous leukemia who have undergone a second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion after relapse.

Adult Glioma Incidence and Survival by Race or Ethnicity in the United States From 2000 to 2014

Abstract Full Text
JAMA Oncol. 2018;4(9):1254-1262. doi:10.1001/jamaoncol.2018.1789

Using 14 years of data from the US Central Brain Tumor Registry and the Surveillance, Epidemiology, and End Results registries, this study examines the incidence and survival rates of glioma and its subtypes among 4 racial or ethnic groups.

Long-term Accuracy of Breast Cancer Risk Assessment Combining Classic Risk Factors and Breast Density

Abstract Full Text
open access online only
JAMA Oncol. 2018;4(9):e180174. doi:10.1001/jamaoncol.2018.0174

This cohort study reports the long-term accuracy of the Tyler-Cuzick model combined with breast density in assessment of risk for breast cancer among women in a state registry.

Brief Report

Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer: Findings From the NRG Oncology RTOG 0618 Trial

Abstract Full Text
JAMA Oncol. 2018;4(9):1263-1266. doi:10.1001/jamaoncol.2018.1251

This analysis of data from a single-arm clinical trial investigates whether stereotactic body radiation therapy delivered on an outpatient basis for patients with operable early-stage lung cancer is associated with primary tumor control, survival, adverse events, and the need for surgical resection.

Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial

Abstract Full Text
open access online only
JAMA Oncol. 2018;4(9):e180077. doi:10.1001/jamaoncol.2018.0077

This preplanned interim analysis of a single-arm clinical trial evaluates the efficacy and safety of avelumab as first-line treatment for patients with distant metastatic Merkel cell carcinoma.

Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series

Abstract Full Text
online only
JAMA Oncol. 2018;4(9):e180219. doi:10.1001/jamaoncol.2018.0219

This observational study examines the activity of anthracycline-based regimens, gemcitabine-based regimens, and pazopanib in patients with advanced epithelioid sarcoma.

Research Letter

Long-term Results of Stereotactic Body Radiation Therapy in Medically Inoperable Stage I Non–Small Cell Lung Cancer

Abstract Full Text
JAMA Oncol. 2018;4(9):1287-1288. doi:10.1001/jamaoncol.2018.1258

This study evaluates 5-year data from the NRG Oncology RTOG 0236 trial on the effects of sterotactic body radiation therapy in patients with inoperable stage I non–small cell lung cancer.

Association of Definitive Pelvic Radiation Therapy With Survival Among Patients With Newly Diagnosed Metastatic Cervical Cancer

Abstract Full Text
JAMA Oncol. 2018;4(9):1288-1291. doi:10.1001/jamaoncol.2018.2677

This cohort study investigates overall survival among patients with newly diagnosed metastatic cervical cancer who received chemotherapy alone compared with those who received chemotherapy and pelvic radiation therapy.

Outcomes From a Minority-Based Lung Cancer Screening Program vs the National Lung Screening Trial

Abstract Full Text
JAMA Oncol. 2018;4(9):1291-1293. doi:10.1001/jamaoncol.2018.2823

This population-based study assesses demographic characteristics, CT scan findings, and lung cancer detection in minority populations compared with outcomes from the National Lung Screening Trial.

Assessment of the Accuracy of Disease Coding Among Patients Diagnosed With Sarcoma

Abstract Full Text
JAMA Oncol. 2018;4(9):1293-1295. doi:10.1001/jamaoncol.2018.2979

This case study compares diagnosis codes with pathology reports for patients diagnosed with sarcoma to assess the accuracy of disease coding at a health care center.

Review

New Business Models to Accelerate Innovation in Pediatric Oncology Therapeutics: A Review

Abstract Full Text
JAMA Oncol. 2018;4(9):1274-1280. doi:10.1001/jamaoncol.2018.1739

This review discusses the problems associated with funding for development of drug therapy to treat cancer in children and proposes a financial model to address the challenges.

JAMA Oncology Clinical Challenge

Disseminated Cutaneous Lesions in a Patient With a Medical History of Myelodysplastic Syndrome

Abstract Full Text
has active quiz
JAMA Oncol. 2018;4(9):1281-1282. doi:10.1001/jamaoncol.2018.0488

A man in his 50s with a medical history of myelodysplastic syndrome refractory anemia with excess blasts presented with a 2-month history of nonpruritic infiltrative skin lesions on the left upper chest. What is your diagnosis?

Viewpoint

The Value of Neoadjuvant Chemotherapy in Localized High-Risk Soft-Tissue Sarcoma of the Extremities and Trunk

Abstract Full Text
JAMA Oncol. 2018;4(9):1167-1168. doi:10.1001/jamaoncol.2018.1392

This Viewpoint argues in favor of using neoadjuvant chemotherapy for the treatment of localized high-risk soft-tissue sarcoma of the extremities and trunk.

Low Levels of Evidence for Neoadjuvant Chemotherapy to Treat Soft-Tissue Sarcoma

Abstract Full Text
JAMA Oncol. 2018;4(9):1169-1170. doi:10.1001/jamaoncol.2018.1403

This Viewpoint argues against using neoadjuvant chemotherapy for the treatment of localized high-risk soft-tissue sarcoma of the extremities and trunk.

Benefits and Harms of the Centers for Medicare & Medicaid Services Ruling on Next-Generation Sequencing

Abstract Full Text
JAMA Oncol. 2018;4(9):1171-1172. doi:10.1001/jamaoncol.2018.1948

This Viewpoint discusses the positive and negative implications of the US national coverage determination for reimbursement for next-generation sequencing by the Centers for Medicare & Medicaid Services.

Invited Commentary

Nuclear Circulating Tumor Cell Androgen Receptor Variant 7 in Castration-Resistant Prostate Cancer: The Devil Is in the Detail

Abstract Full Text
JAMA Oncol. 2018;4(9):1187-1188. doi:10.1001/jamaoncol.2018.1615

In Search of an Oncogene Driver for Squamous Lung Cancer

Abstract Full Text
JAMA Oncol. 2018;4(9):1197-1198. doi:10.1001/jamaoncol.2018.0774

Broadening the View of Germline Mutations in Kidney Cancer

Abstract Full Text
JAMA Oncol. 2018;4(9):1235-1236. doi:10.1001/jamaoncol.2018.2015
JAMA Oncology Patient Page

I Have Neutropenia—What Do I Need to Know?

Abstract Full Text
free access
JAMA Oncol. 2018;4(9):1307. doi:10.1001/jamaoncol.2018.2653

This Patient Page provides information on neutropenia, a condition associated with having an abnormally low number of neutrophils in the blood resulting in increased risk of infection.

Cancer Care Chronicles

The Power of Trust

Abstract Full Text
JAMA Oncol. 2018;4(9):1173-1174. doi:10.1001/jamaoncol.2018.0495

This article discusses a community support group for patients with neuroendocrine tumors, and learning to build trust as a team.

Comment & Response

Database Selection and Heterogeneity—More Details, More Credibility

Abstract Full Text
JAMA Oncol. 2018;4(9):1295. doi:10.1001/jamaoncol.2018.1209

Database Selection and Heterogeneity—More Details, More Credibility—Reply

Abstract Full Text
JAMA Oncol. 2018;4(9):1295-1296. doi:10.1001/jamaoncol.2018.1231

The Objective of Local Therapy in Oligometastatic Cancer Is a Moving Target

Abstract Full Text
JAMA Oncol. 2018;4(9):1296. doi:10.1001/jamaoncol.2018.1225

The Objective of Local Therapy in Oligometastatic Cancer Is a Moving Target—Reply

Abstract Full Text
JAMA Oncol. 2018;4(9):1296-1297. doi:10.1001/jamaoncol.2018.1228

Beyond Primary Tumor Location and RAS/BRAF Mutational Status as Prognostic Factor in Stage III Colon Cancer

Abstract Full Text
JAMA Oncol. 2018;4(9):1297-1298. doi:10.1001/jamaoncol.2018.1692

Beyond Primary Tumor Location and RAS/BRAF Mutational Status as Prognostic Factor in Stage III Colon Cancer—Reply

Abstract Full Text
JAMA Oncol. 2018;4(9):1298. doi:10.1001/jamaoncol.2018.1718

Paclitaxel and Pazopanib in Ovarian Cancer

Abstract Full Text
JAMA Oncol. 2018;4(9):1298-1299. doi:10.1001/jamaoncol.2018.1695

Paclitaxel and Pazopanib in Ovarian Cancer—Reply

Abstract Full Text
JAMA Oncol. 2018;4(9):1299. doi:10.1001/jamaoncol.2018.1712

Clarification of the FDA Accelerated Agnostic Approval of Pembrolizumab and the Opportunities Arising From the Required Confirmatory Studies

Abstract Full Text
JAMA Oncol. 2018;4(9):1299-1300. doi:10.1001/jamaoncol.2018.1709

Clarification of the FDA Accelerated Agnostic Approval of Pembrolizumab and the Opportunities Arising From the Required Confirmatory Studies—Reply

Abstract Full Text
JAMA Oncol. 2018;4(9):1300-1301. doi:10.1001/jamaoncol.2018.1715

Optimal Multimodal Treatment for Desmoplastic Small Round Cell Tumors

Abstract Full Text
JAMA Oncol. 2018;4(9):1301. doi:10.1001/jamaoncol.2018.2146

Optimal Multimodal Treatment for Desmoplastic Small Round Cell Tumors—Reply

Abstract Full Text
JAMA Oncol. 2018;4(9):1301-1302. doi:10.1001/jamaoncol.2018.2149
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2018;4(9):1158. doi:10.1001/jamaoncol.2017.3246
In This Issue of JAMA Oncology

Highlights

Abstract Full Text
free access
JAMA Oncol. 2018;4(9):1153. doi:10.1001/jamaoncol.2017.3245
×